Radiation exposure and radiation protection of the physician in iodine-131 Lipiodol therapy of liver tumours.
Intra-arterial iodine-131 labelled Lipiodol therapy for liver cancer has been investigated for safety and efficacy over a number of years, but data on radiation exposure of personnel have remained unavailable to date. The aim of this study was to assess the radiation exposure of the physician during intra-arterial 131I-Lipiodol therapy for liver malignancies and to develop appropriate radiation protection measures and equipment. During 20 intra-arterial administrations of 131I-Lipiodol (1110-1924 MBq), radiation dose equivalents (RDE) to the whole body, fingers and eyes of the physician were determined for (a) conventional manual administration through a shielded syringe, (b) administration with an automatic injector and (c) administration with a lead container developed in-house. Administration by syringe resulted in a finger RDE of 19.5 mSv, an eye RDE of 130-140 microSv, and a whole-body RDE of 108-119 microSv. The injector reduced the finger RDE to 5 mSv. With both technique (a) and technique (b), contamination of angiography materials was observed. The container allowed safe transport and administration of the radiopharmaceutical from 4 m distance and reduced the finger RDE to <3 microSv and the eye RDE to <1 microSv during injection. During femoral artery compression, radiation exposure to the fingers reached 170 microSv, but the whole-body dose could be reduced from a mean RDE of 114 microSv to 14 microSv. No more contamination occurred. In conclusion, radiation exposure was high when 131I-Lipiodol was administered by syringe or injector, but was significantly reduced with the lead container.
Risse
J H
JH
Department of Nuclear Medicine, University of Frankfurt/Main, Germany. J.Risse@em.uni-frankfurt.de
Ponath
C
C
Palmedo
H
H
Menzel
C
C
Grünwald
F
F
Biersack
H J
HJ
D006801:Humans; D007269:Injections, Intra-Arterial / Q000295:instrumentation / Q000379:methods; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000532:radiotherapy*; D016273:Occupational Exposure; D011829:Radiation Dosage; D018787:Radiation Oncology; D011835:Radiation Protection / Q000295:instrumentation / Q000379:methods; D015641:Radiography, Interventional
D007457:Iodine Radioisotopes; D007459:Iodized Oil